Business Wire

Patent Pool May Be a Key Factor in Open RAN Adoption, Report Says

Share

A patent pool may play a key role in the adoption of Open RAN technology, according to a recent report published by Harvard Business School Professor Josh Lerner and Bella Private Markets.

The report entitled “Accelerating innovation in connectivity: The case for an Open RAN patent pool”, which can be found here, was commissioned by Alium, a joint venture between MPEG LA and Unified Patents. Alium launched the Open RAN Patent Portfolio License last year. See https://www.alium-llc.com/blog/alium-introduces-open-ran-patent-portfolio-license

"Patent pools have historically played a critical role in supporting innovation by reducing risks around intellectual property and encouraging investment in new technologies. One such technology is Open RAN, a key component in unlocking widespread 5G adoption,” said Professor Lerner. “The Alium pool represents one effort to accelerate the adoption of Open RAN and help realize its many potential benefits."

“We appreciate the work of Josh Lerner and Bella Private Markets demonstrating a patent pool’s role in the adoption of Open RAN technology,” said Craig Thompson, a licensing executive at Alium. “While Open RAN has the potential to reshape the market for mobile telecommunications by increasing vendor diversity, lowering costs and energy consumption, facilitating wider adoption of 5G, and giving operators greater control over their networks, it relies on a crowded and complex patent landscape with little or no royalty benchmarking information. That’s where the Alium Patent Pool comes in. Based on our experience, we are confident that Alium’s Open RAN Patent Pool will reduce royalty stacking, hold-up, and expensive litigation risks, helping Open RAN implementers save billions in costs while accelerating future revenue growth, profitability, and new service deployments.”

Alium’s objective is to offer worldwide access to as many Open RAN essential patents as possible to everyone on the same terms under a single license. Alium welcomes the participation of any party with at least one patent that is essential to the Open RAN Standard. For more information, please go to https://www.alium-llc.com/licensors.

Josh Lerner and Bella Private Markets

Bella Private Markets focuses exclusively on providing solutions to the challenges facing the private capital industry. Led by Harvard Business School Professor Dr. Josh Lerner, Bella combines rigorous academic approaches with real world industry expertise to provide actionable insights for its clients. Bella focuses on complex, customized projects that require thorough analysis, whether quantitative or qualitative in nature, to help its clients improve performance, optimize operations, and chart winning strategies for the future.

Alium

Alium, a joint venture between MPEG LA and Unified Patents, supports Open RAN with the first patent pool for telecommunications infrastructure. Open RAN provides network operators with greater control and flexibility in deploying 4G and next generation 5G networks, and the Alium patent pool provides a one-stop solution to the uncertainty and risk posed by as many as tens of thousands of patents owned by numerous patent owners that cover the 3GPP standardized lower physical layer functionalities performed by radio units applying the O-RAN Alliance’s 7-2x baseband architecture split.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tom O’Reilly
Alium
Tel: 303.200.1710
tom@alium-llc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye